# Peter Neubeck

> Peter Neubeck is a Series A investor at Kurma Partners backing Health Care and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners)
- Location: Munich, Germany
- Total investments: 10
- Last investment: Apr 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/peterneubeck/

Peter Neubeck is a Series A investor at Kurma Partners in Munich focused on Health Care and Biotechnology. Peter Neubeck is based out of Munich, Bayern and is the partner of Kurma Partners. Peter previously worked at Emergence Therapeutics as a chair of the board of directors. Peter Neubeck attended the Ludwig-Maximilians-Universität München.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 50% |
| Biotechnology | 4 | 40% |
| Therapeutics | 3 | 30% |
| CRM | 1 | 10% |
| Fitness | 1 | 10% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 50% |
| Seed | 2 | 20% |
| Funding Round | 1 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 3 | 30% |
| France | 2 | 20% |
| Spain | 1 | 10% |
| Switzerland | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M | Seed | Apr 29, 2026 |  |
| Adcytherix | Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M | Series A | Oct 16, 2025 |  |
| SciRhom | SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development. | $68.1M | Series A | Jul 09, 2024 |  |
| Corteria Pharmaceuticals | Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $69.5M | Series A | Sep 07, 2023 |  |
| Corteria Pharmaceuticals | Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $13.6M | Seed | Dec 09, 2021 |  |
| Emergence Therapeutics | Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as anADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need. | $98.1M | Series A | Dec 07, 2021 |  |
| Medlumics | Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology. | $21.8M | Venture - Series Unknown | Feb 10, 2021 |  |
| Synendos Therapeutics | Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders. The company also develops breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of the naturalfunctioning of the brain.The inhibitors act with a new mechanism of action that enables restoration of the natural function of the brain by rebalancing altered neurotransmission in different areas of the bran. There is a high demand for new pharmacological treatments in this area especially for certain diseases such as post-traumatic stress disorder (PTSD) which has a high unmet medical need. | $23.3M | Series A | Nov 12, 2020 |  |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $7.4M | Seed | Sep 25, 2019 |  |
| Tacalyx | Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $7.4M | Seed | Sep 25, 2019 |  |

10 of 10 investments shown.

## Co-investors
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 6 deals together
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 3 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 3 deals together
- [Creathor Ventures](https://shizune.co/investors/profile/creathor-venture-management) — VC Fund, 3 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 3 deals together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 3 deals together

## About Kurma Partners

VC Fund · Paris, France

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

5 contacts available at Kurma Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alain Horvais | Partner | https://shizune.co/investors/profile/alain-horvais |
| Amanda Gett Chaperot | Partner | https://shizune.co/investors/profile/amanda-gett |
| Amine Marouf | Principal | https://shizune.co/investors/profile/amine-marouf |
| Peter Neubeck | Partner | https://shizune.co/investors/profile/peter-neubeck |
| Philippe Peltier | Partner | https://shizune.co/investors/profile/philippe-peltier |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Peter Neubeck invest in?

Peter Neubeck invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Peter Neubeck last invest?

The most recent investment recorded for Peter Neubeck closed in Apr 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co